Abstracts Archive - Page 1411 of 2607 - ACR Meeting Abstracts

Abstract Number: 356 • 2017 ACR/ARHP Annual Meeting
Preliminary Real World Data on Switching Patterns between Etanercept, Its Recently Marketed Biosimilar Counterpart and Its Competitor Adalimumab, Using Swedish Prescription Registry
Rieke Alten¹, Petra Neregard², Heather Jones³, Ena Singh⁴, Cinzia Curiale⁵, Thomas Meng⁶, Lara Lucchese⁷, Cristiana Miglio⁷ and Gudrun Jonasdottir Bergman⁸, ¹Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ²Pfizer, Stochholm, Sweden, ³Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA, ⁵Pfizer, Rome, Italy, ⁶Pfizer, Berlin, Germany, ⁷QuintilesIMS, London, United Kingdom, ⁸QuintilesIMS, Solna, Sweden
Background/Purpose: The increasing availability of biologic treatments over the past 10 years has revolutionized the management of rheumatic diseases. In April 2016, the first etanercept…
Abstract Number: 357 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient and Physician Disagreement on Presence of a Gout Flare
Aprajita Jagpal¹, Nicola Dalbeth², William J. Taylor³, Kenneth Saag¹, Jasvinder A. Singh⁴, Amy S. Mudano⁵, Elizabeth J. Rahn⁶ and Angelo L. Gaffo⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Wellington, New Zealand, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flare is a central feature of gout and patient self-report of flare was found to be an important element in a gout flare definition…
Abstract Number: 358 • 2017 ACR/ARHP Annual Meeting
Patients and Physicians Have Different Perceptions of the Relative Bother of the Symptoms and Impacts on Daily Activities in Psoriasis and Psoriatic Arthritis
M. Elaine Husni^1,2, Anthony Fernandez¹, Rakesh Singh³, Brett Hauber⁴, Jessie Sutphin⁴, Joshua Posner⁴ and Arijit Ganguli³, ¹Cleveland Clinic, Cleveland, OH, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³AbbVie Inc., North Chicago, IL, ⁴RTI Health Solutions, Research Triangle Park, NC
Background/Purpose: Psoriasis and psoriatic arthritis arise from the same immune system response but result in different symptoms and impacts on daily activities. A patient with…
Abstract Number: 359 • 2017 ACR/ARHP Annual Meeting
Nurse Telephone Education for Promoting a Treat-to-Target Approach in Recently Diagnosed Rheumatoid Arthritis Patients – a Preliminary Review
Bonita Libman¹, Siobhan Farley¹, Melinda Edwards¹, Carl Possidente² and Amanda Kennedy³, ¹Medicine/Rheumatology, University of Vermont Medical Center, Burlington, VT, ²Medical Affairs, Pfizer, Inc., Jericho Center, VT, ³Internal Medicine, University of Vermont, Burlington, VT
Background/Purpose: A successful Treat-to-Target approach to managing Rheumatoid Arthritis (RA) requires shared decision making with patients and healthcare providers. However patients may not have the…
Abstract Number: 360 • 2017 ACR/ARHP Annual Meeting
Evaluation of the Educational Needs in Argentinian Patients with Rheumatoid Arthritis Using the SpENAT Questionnaire
Silvana Karina Pérez¹, Maria Julia Santa Cruz¹, María Alejandra Medina¹, Diana Klajn², Silvia Beatriz Papasidero¹, Jose Angel Caracciolo¹, Gisela Pendón³, Federico Giordano⁴, Dora Pereira⁵, Damaris Alvarez⁶, Valeria Astudillo⁶, Eduardo Kerzberg⁶, Adriana Perez Davila⁷, Analia Bohr⁷, Fernando Melo⁸, Nicolas Lloves⁸, Marta Mamani⁹, Claudia Hartvig¹⁰, Gabriela Sanchez¹⁰, Monica Sacnun¹⁰, Yamila Chichotky¹¹, José Velasco Zamora¹¹, Mariana Benegas¹², Javier Rosa¹³, Maria Victoria Garcia¹⁴, Laura Raiti¹⁵, Vanesa Cruzat¹⁵, Rosana Quintana¹⁶, Bernado Pons-Estel¹⁷, Karin Kirmayr¹⁸, Andrea D'Orazio¹⁹, Cinthya Retamozo²⁰, Olga Romano²¹, Rodolfo Perez-Alamino²¹, María de los Angeles Correa²², Gustavo Citera²³, Oscar Rillo²⁴, María Marta Zalazar²⁴, Ana Carolina Costi²⁵, Mercedes Argentina García²⁵, Graciela Gómez²⁶ and Hernán Maldonado Ficco²⁷, ¹Rheumatology Department, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Research Committee, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ³Hospital Ricardo Gutierrez, La Plata, Argentina, ⁴Rheumatology Department, Hospital Ricardo Gutierrez, La Plata, Buenos Aires, Argentina, ⁵Rheumatology Department, Hospital Ricardo Gutierrez, Buenos Aires, Argentina, ⁶Rheumatology Department, Hospital Ramos Mejía, Buenos Aires, Argentina, ⁷Rheumatology Department, Hospital de Rehabilitación Manuel Rocca, Buenos Aires, Argentina, ⁸Rheumatology Department, Hospital Rivadavia, Buenos Aires, Argentina, ⁹Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Rheumatology Department, Hospital Provincial de Rosario, Santa Fe, Argentina, ¹¹Rheumatology Department, Reumatologia al sur, Buenos Aires, Argentina, ¹²Rheumatology Department, Sanatorio de la Providencia, Buenos Aires, Argentina, ¹³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ¹⁴Rheumatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁵Rheumatology Department, Clinica Bessone, Buenos Aires, Argentina, ¹⁶Rheumatology Department, Sanatorio Parque, Rosario, Santa Fe, Argentina, ¹⁷GLADEL, Rosario, Santa Fe, Argentina, ¹⁸Rheumatology Department, Sanatorio San Carlos, Bariloche, Argentina, ¹⁹Rheumatology Department, Hospital Interzonal Dr. José Penna, Bahia Blanca, Buenos Aires, Argentina, ²⁰Rheumatology Department, Centro Especializado Diabetes y Reumatologia, Salta, Argentina, ²¹Rheumatology Department, Hospital de Clínicas Pte. Dr. Nicolás Avellaneda, Tucumán, Argentina, ²²Section Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Buenos Aires, Argentina, ²³Rheumatology Department, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²⁴Rheumatology Department, Hospital General de Agudos Dr. Ignacio Pirovano, Buenos Aires, Argentina, ²⁵Rheumatology Department, Hospital Interzonal General de Agudos Gral. José de San Martín, La Plata, Buenos Aires, Argentina, ²⁶Rheumatology Department, Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ²⁷section of Rheumatology, Clinica Regional del Sud, Córdoba, Argentina, Córdoba, Argentina
Background/Purpose: The SpENAT, a Spanish version of the Educational Needs Assessment Tool, is a self-completed questionnaire that assesses educational needs (ENs) with the purpose of…
Abstract Number: 361 • 2017 ACR/ARHP Annual Meeting
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Jasmin B. Kuemmerle-Deschner¹, Pierre Quartier², Shai Padeh³, Isabelle Koné-Paut⁴, Veronique Hentgen⁵, Katherine A. Marzan⁶, Fatma Dedeoglu⁷, Helen J. Lachmann⁸, Tilmann Kallinich⁹, Norbert Blank¹⁰, Seza Ozen¹¹, Yelda Bilginer¹², Jonathan S. Hausmann^7,13, Arturo Diaz¹³, Ravi Degun¹⁴, Nina Marinsek¹⁴, Jill Gregson¹⁵, Kathleen G. Lomax¹⁶ and Avi Livneh¹⁷, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³Sheba Medical Center, Tel-Hashomer, Israel, ⁴Bicêtre Hospital, APHP, Univeristy Paris Sud, Paris, France, ⁵Versailles Hospital, CEREMAI, Le Chesnay, France, ⁶Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁷Boston Children's Hospital, Boston, MA, ⁸UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁹Charité, Humbolt University Medicine Berlin, Berlin, Germany, ¹⁰UniversitätsKlinikum Heidelberg, Heidelberg, Germany, ¹¹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹²Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹³Beth Israel Deaconess Medical Center, Boston, MA, ¹⁴Life Sciences, Navigant Consulting, London, United Kingdom, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Sheba Medical Center, Ramat-Gan, Israel
Background/Purpose: Periodic fever syndromes (PFS) are a group of autoinflammatory disorders characterized by recurrent bouts of fever and severe localized inflammation which, if not treated,…
Abstract Number: 362 • 2017 ACR/ARHP Annual Meeting
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Amanda Teeple¹, Lorie A. Ellis², Laura Huff³, Chuck Reynolds³, Seth D. Ginsberg⁴, Leah McCormick Howard⁵, Danielle Walls⁶ and Jeffrey R. Curtis⁷, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ³Benfield | Arthur J. Gallagher & Co., Webster Groves, MO, ⁴Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁵National Psoriasis Foundation, Portland, OR, ⁶BDJ Solutions, Melrose, MA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health insurance plan designs often have benefits that result in highly prescriptive patient (pt) treatment options that can result in switching of patient’s medications…
Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Mahdi Gharaibeh¹, Bradley S. Stolshek², Alex Mutebi³, Amy M. Sainski-Nguyen⁴, David Collier⁵ and Emily Durden⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Thousand Oaks, CA, ⁴Truven Health Analytics, Ann Arbor, MI, ⁵Amgen, Inc, Terni, Italy
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…
Abstract Number: 364 • 2017 ACR/ARHP Annual Meeting
Canakinumab First or Second Choice in Systemic Juvenile Idiopathic Arthritis – Experience from Clinical Practice
Gerd Horneff¹, Ivan Foeldvari², Klaus Tenbrock³, K Minden⁴ and Jasmin B. Kuemmerle-Deschner⁵, ¹Asklepios Clinic, Sankt Augustin, Germany, ²Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ³University Aachen, Aachen, Germany, ⁴Charité – University of Medicine Berlin, Berlin, Germany, ⁵Pediatrics, University Hospital Tübingen, Tübingen, Germany
Background/Purpose: Canakinumab (CAN) has demonstrated its efficacy and safety in systemic juvenile idiopathic arthritis in clinical trials. We report on the experience with CAN in…
Abstract Number: 365 • 2017 ACR/ARHP Annual Meeting
Canakinumab Treatment in Patients with Still’s Disease: A Pooled Analysis of Systemic Juvenile Idiopathic Arthritis Data By Age Groups
Eugen Feist¹, Pierre Quartier², Bruno Fautrel³, Rayfel Schneider⁴, Paolo Sfriso⁵, Petros Efthimiou⁶, Luca Cantarini⁷, Karine Lheritier⁸, Karolynn Leon⁹ and Antonio Speziale⁸, ¹Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁴University of Toronto and The Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Padova, Padova, Italy, ⁶Medicine/Rheumatology, New York University School of Medicine/NYU Langone Health, New York, NY, ⁷University of Siena, Siena, Italy, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Still’s disease presents in pediatric and adult patients as a disease continuum with similar symptoms and pathophysiology.1,2 The objective of this analysis was to…
Abstract Number: 366 • 2017 ACR/ARHP Annual Meeting
Short-Term Outcomes in Patients with Systemic-Onset Juvenile Idiopathic Arthritis Treated with Either Tocilizumab or Anakinra in a Real-World Setting in the United Kingdom
Lianne Kearsley-Fleet¹, Diederik De Cock¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson^6,7 and Kimme L. Hyrich^1,6, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Clinical Academic Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine and Paediatric Rheumatology, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Juvenile idiopathic arthritis (JIA) comprises 7 ILAR categories, but systemic-onset JIA (sJIA) appears to be distinct in genetic background and pathogenesis from the other…
Abstract Number: 367 • 2017 ACR/ARHP Annual Meeting
Interleukin-1 Receptor Antagonist Is a Potential Treatment for Undifferentiated Autoinflammatory Syndromes
Ananta Subedi¹, Daniella Schwartz², Karyl Barron³, Daniel L. Kastner⁴ and Amanda Ombrello⁵, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²NIAMS - Rheumatology, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵Inflammatory Disease Section, NHGRI/NIH, Bethesda, MD
Background/Purpose: The autoinflammatory diseases (AIDs) are a group of disorders of the innate immune system characterized by seemingly unprovoked inflammation1. A variety of genetic alterations…
Abstract Number: 368 • 2017 ACR/ARHP Annual Meeting
Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever
Kenan Barut, Amra Adrovic, Sezgin Sahin, Asli Kaplan and Ozgur Kasapcopur, Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: The colchicine-resistant FMF (crFMF) is defined as 6 or more polyserositis attacks in the last year despite the regular usage of colchicine in the…
Abstract Number: 369 • 2017 ACR/ARHP Annual Meeting
Hepatitis A Virus Vaccination in Juvenile-Onset Systemic Lupus Erythematosus
Sevinc Mertoglu¹, Sezgin Sahin¹, Omer Faruk Beser², Amra Adrovic¹, Kenan Barut¹, Pelin Yuksel³, Soner Sazak⁴, Bekir Kocazeybek⁵ and Ozgur Kasapcopur¹, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Pediatric Gastroenterology, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ³Microbiology, Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey, ⁴Pediatrics, Department of Pediatrics, Okmeydani Education and Training Hospital, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical School, Department of Microbiology, Istanbul, Turkey
Background/Purpose: Various infections play significant roles in flares of systemic lupus erythematosus (SLE). Hepatitis A virus is one of these infectious agents that has high…
Abstract Number: 370 • 2017 ACR/ARHP Annual Meeting
Validation of 2016 ACR/EULAR Classification Criteria of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis in Japanese Patients
Masaki Shimizu¹, Mao Mizuta¹, Takahiro Yasumi², Naomi Iwata³, Yuka Okura⁴, Noriko Kinjo⁵, Hiroaki Umebayashi⁶, Tomohiro Kubota⁷, Yasuo Nakagishi⁸, Kenichi Nishimura⁹, Masato Yashiro¹⁰, Junko Yasumura¹¹, Kazuko Yamazaki¹², Hiroyuki Wakiguchi¹³, Nami Okamoto¹⁴ and Masaaki Mori¹⁵, ¹Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ²Department of Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, ⁴Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, ⁵Department of Pediatrics, Faculty of medicine, University of the Ryukyus, Nakagami-gun, Japan, ⁶Department of Rheumatics, Miyagi Children’s Hospital, Sendai, Japan, ⁷Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ⁸Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, ⁹Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹⁰Department of Pediatrics, Okayama University Hospital, Okayama, Japan, ¹¹Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, ¹²Department of Pediatrics, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, ¹³Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan, ¹⁴Department of Pediatrics, Osaka Medical College, Takatsuki, Japan, ¹⁵Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: To validate the 2016 ACR/EULAR classification criteria of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA) in Japanese patients. Methods: A combination…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].